Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Imaging of Dissection of the Descending Aorta (DADI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01648881
Recruitment Status : Completed
First Posted : July 24, 2012
Last Update Posted : September 18, 2019
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Patients with dissection of the descending aorta will be followed up according to a precise timeline.

Condition or disease Intervention/treatment
Dissection of the Descending Aorta Radiation: TEP-18FDG for every patient after aortic dissection

Detailed Description:
NMR baseline A PET Scanner will be performed minimum 3 months post dissection 6 months and every year during three years after PET scanner : CT scanner and blood sample

Layout table for study information
Study Type : Observational
Actual Enrollment : 89 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dissection of Aorta: Descending Part, Imaging
Actual Study Start Date : May 2011
Actual Primary Completion Date : December 2015
Actual Study Completion Date : August 2019

Resource links provided by the National Library of Medicine



Intervention Details:
  • Radiation: TEP-18FDG for every patient after aortic dissection

    Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.

    Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

    Other Name: TEP-18FDG



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with dissection of the descending aorta
Criteria

Inclusion Criteria:

  • 18 years
  • Seen for dissection of the descending aorta
  • Dissection of the descending aorta within the last three months
  • Affiliation to social security
  • Signed informed consent

Exclusion Criteria:

  • intervention programmed in relation with dissection of the descending aorta
  • Pregnant female
  • Adults without legal capacity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01648881


Locations
Layout table for location information
France
Pr Guillaume JONDEAU . Cardiologie. Hôpital Bichat
Paris, Ile De France, France, 75018
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Layout table for investigator information
Principal Investigator: Guillaume JONDEAU Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01648881    
Other Study ID Numbers: P 100505
2011-A00238-33 ( Other Identifier: ID RCB )
First Posted: July 24, 2012    Key Record Dates
Last Update Posted: September 18, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action